ImmunoPrecise Antibodies Ltd. (IPA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IPA POWR Grades
- IPA scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.5% of US stocks.
- The strongest trend for IPA is in Sentiment, which has been heading up over the past 32 days.
- IPA's current lowest rank is in the Quality metric (where it is better than 6.59% of US stocks).
IPA Stock Summary
- IPA's went public 2.24 years ago, making it older than only 9.64% of listed US stocks we're tracking.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.28 for IMMUNOPRECISE ANTIBODIES LTD; that's greater than it is for just 17.07% of US stocks.
- With a year-over-year growth in debt of 146.39%, IMMUNOPRECISE ANTIBODIES LTD's debt growth rate surpasses 91.29% of about US stocks.
- Stocks that are quantitatively similar to IPA, based on their financial statements, market capitalization, and price volatility, are VMAR, OPGN, INM, ONDS, and SNCR.
- Visit IPA's SEC page to see the company's official filings. To visit the company's web site, go to www.immunoprecise.com.
IPA Price Target
For more insight on analysts targets of IPA, see our IPA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $16.17 | Average Broker Recommendation | 1.5 (Moderate Buy) |
IPA Stock Price Chart Interactive Chart >
IPA Price/Volume Stats
| Current price | $2.77 | 52-week high | $6.50 |
| Prev. close | $2.82 | 52-week low | $2.64 |
| Day low | $2.76 | Volume | 21,500 |
| Day high | $2.85 | Avg. volume | 41,345 |
| 50-day MA | $3.91 | Dividend yield | N/A |
| 200-day MA | $4.62 | Market Cap | 69.07M |
ImmunoPrecise Antibodies Ltd. (IPA) Company Bio
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Latest IPA News From Around the Web
Below are the latest news stories about IMMUNOPRECISE ANTIBODIES LTD that investors may wish to consider to help them evaluate IPA as an investment opportunity.
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with AstellasVICTORIA, British Columbia, March 30, 2023--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company") an AI-driven biotherapeutic research and technology company today announced a research collaboration and exclusive option license agreement with Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas Pharma Inc., "Astellas"). Under the terms of the agreement, the companies will jointly conduct research activities to identify and optimize proprietary LENSai |
European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® TechnologyVICTORIA, British Colombia, March 27, 2023--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) ("Immunoprecise" or "IPA" or the "Company"), the parent company of BioKey and affiliate of BioStrand, announced today that the EPO has issued a "Decision to Grant" for BioKey’s patent application covering the company’s HYFT® Technology used to organize and analyze biological sequence information. The HYFT Technology and methodology provide a novel way to efficiently tap into sequence information, allowing the |
ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival RatesVICTORIA, British Colombia, March 23, 2023--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) ("Immunoprecise" or "IPA" or the "Company"), an AI-driven biotherapeutic research and technology company, is pleased to announce that its wholly owned subsidiary, Talem Therapeutics, will present a scientific poster with their latest data on the development of bispecific T-cell engagers targeting TrkB at the annual AACR meeting in Orlando, Florida, which is held from April 14 to 19, 2023. With this advanced d |
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023VICTORIA, British Columbia, March 16, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal year 2023, which ended January 31, 2023. |
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera BioVICTORIA, British Columbia & SANTIAGO DE COMPOSTELA, Spain, March 15, 2023--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) ("Immunoprecise" or "IPA" or the "Company"), an AI-driven biotherapeutic research and technology company, today announced that Talem Therapeutics LLC, an independently operating subsidiary of IPA, and Libera Bio S.L., have signed a collaboration agreement to jointly address intracellular targets. It is estimated that 75% of disease-causing targets are located inside cells1. Som |
IPA Price Returns
| 1-mo | -31.68% |
| 3-mo | -46.83% |
| 6-mo | -40.81% |
| 1-year | -46.63% |
| 3-year | 2.59% |
| 5-year | N/A |
| YTD | -46.83% |
| 2022 | -2.80% |
| 2021 | -64.15% |
| 2020 | 579.08% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...